Last reviewed · How we verify
Placebo for toripalimab
Placebo is an inert substance with no active pharmacological mechanism.
Placebo is an inert substance with no active pharmacological mechanism. Used for Control arm in phase 3 trials of toripalimab for cancer indications.
At a glance
| Generic name | Placebo for toripalimab |
|---|---|
| Sponsor | Shanghai Junshi Bioscience Co., Ltd. |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Placebo serves as a control comparator in clinical trials and contains no active pharmaceutical ingredient. It is used to establish the baseline efficacy and safety profile of the investigational drug toripalimab (a PD-1 inhibitor) by comparison against a non-therapeutic control arm.
Approved indications
- Control arm in phase 3 trials of toripalimab for cancer indications
Common side effects
Key clinical trials
- SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and Anxiety (PHASE2)
- Phase III Study of Toripalimab（JS001） Combined With Lenvatinib for Advanced HCC (PHASE3)
- Clinical Study of Chemotherapy and Immunotherapy Combined With Lactobacillus Johnsonii in Patients With Multiple Irresectable Solid Tumors (NA)
- The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer (PHASE3)
- Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment (PHASE3)
- Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study (PHASE3)
- Toripalimab Vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma (PHASE3)
- PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo for toripalimab CI brief — competitive landscape report
- Placebo for toripalimab updates RSS · CI watch RSS
- Shanghai Junshi Bioscience Co., Ltd. portfolio CI